Truvestments Capital’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Truvestments Capital’s Portfolio SBIO Stock Details SBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$20K	Buy	+520	New	+$19.7K	0.01%	514

Other funds holding SBIO

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BCM

Barometer Capital Management Toronto, Ontario, Canada $292M AUM 86.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

NAM

NTV Asset Management Charleston, West Virginia $910M AUM 27.02% 1-Year Est. Return

Cavalier Investments Alpharetta, Georgia $3.7B AUM 51.42% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Truvestments Capital's SBIO Position: Q3 2018 in Review

Truvestments Capital opened a new position in ALPS Medical Breakthroughs ETF (SBIO) in Q3 2018: 520 shares worth $20K. The stake represents 0.01% of the portfolio and ranks #514 among its holdings.

55 funds tracked by Wall St. Rank hold SBIO as of Q3 2018.

Truvestments Capital held 520 shares of ALPS Medical Breakthroughs ETF worth $20K as of Q3 2018.
ALPS Medical Breakthroughs ETF was a new Truvestments Capital position in Q3 2018.
ALPS Medical Breakthroughs ETF made up 0.01% of Truvestments Capital's portfolio in Q3 2018, its #514 holding.
55 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q3 2018.

Based on Truvestments Capital's 13F filing for Q3 2018, filed 22 Oct 2018.